查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1950486

免疫查核點抑制劑癌症市場：依作用機制、治療方式、治療階段、最終使用者和適應症分類－全球預測，2026-2032年

Immune Checkpoint Inhibitors for Cancer Market by Mechanism Of Action, Treatment Modality, Therapy Line, End User, Indication - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 189 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，癌症免疫查核點抑制劑市場價值將達到 472.5 億美元，到 2026 年將成長至 521 億美元，到 2032 年將達到 921.5 億美元，複合年成長率為 10.01%。

關鍵市場統計數據
基準年 2025 472.5億美元
預計年份：2026年 521億美元
預測年份 2032 921.5億美元
複合年成長率 (%) 10.01%

本文簡要概述了免疫查核點抑制劑如何透過適應症、作用機制、聯合治療和醫療服務模式重塑腫瘤學實踐。

過去十年間，免疫查核點抑制劑已從一項科學突破發展成為多種腫瘤適應症的標準治療支柱，挑戰傳統的癌症治療和護理模式。這些藥物透過調節免疫查核點來恢復抗腫瘤免疫力，如今正影響著臨床實踐，並影響著包括膀胱癌、頭頸癌、黑色素瘤、非小細胞肺癌和腎細胞癌在內的多種固態腫瘤的治療決策。在非小細胞肺癌中，非鱗狀細胞癌和鱗狀細胞癌的組織學差異指導不同的臨床策略；而在腎細胞癌中，透明細胞癌和非透明細胞癌亞型的區分則要求在患者選擇和聯合治療設計方面採取個體化方法。

不斷發展的生物標記精準度、聯合治療、監管合規性和供應鏈策略如何重新定義免疫查核點療法的競爭優勢

隨著科學、臨床和商業性因素的融合，免疫查核點抑制劑領域正經歷變革性的轉變，重新定義了治療標準和投資重點。生物標記科學的進步正在改善患者選擇，使PD-1和PD-L1拮抗劑的應用更加精準，並為CTLA-4標靶治療方案的設計提供資訊。同時，將查核點抑制劑與化療、標靶治療或其他免疫療法結合的聯合治療策略，透過擴大潛在有效人群和改變毒性特徵，正在改變治療格局。這些針對腫瘤生物學進行策略性調整的聯合治療治療方案，在多種治療環境中均取得了顯著的療效提升，因此亟需開發新的安全通訊協定和跨學科的診療模式。

評估美國 2025 年關稅政策的變化將如何影響供應鏈、製造選擇、臨床操作和商業合約動態。

預計2025年美國貿易政策的變化和關稅調整將對依賴跨境供應鏈獲取生物製藥、原料以及免疫查核點抑制劑生產所需特殊組件的利益相關人員產生重要影響。儘管許多核心生物程序仍保持區域集中，但關鍵投入品、包裝和實驗室設備的關稅上漲可能會增加成本壓力。這些壓力可能導致契約製造製造商、申辦者和臨床試驗供應商的營運成本增加，進而影響生產地點選擇、庫存策略和供應商多元化決策。

深入的細分洞察查核點抑制劑的臨床和商業性策略與適應症亞型、作用機制細微差別、治療方法方案、治療線和臨床環境聯繫起來。

了解不同病患群體和醫療機構中查核點抑制劑的臨床效用、商業性路徑和營運重點，必須採用細分觀點。對適應症的檢驗揭示了不同的治療需求。膀胱癌、頭頸癌、黑色素瘤、非小細胞肺癌和腎細胞癌均表現出獨特的腫瘤生物學特性和反應模式，這會影響臨床實驗設計和監管策略。在非小細胞肺癌中，非鱗狀細胞癌和鱗狀細胞癌的組織學類型決定了不同的臨床治療方案，進而影響合併用藥的選擇和生物標記的重點。同時，腎細胞癌又分為透明細胞癌和非透明細胞癌亞型，因此需要針對不同亞型特異性終點指標並制定個人化的組合方案。

區域間在監管、支付系統、臨床試驗生態系統和生產能力方面的差異將如何影響全球市場的准入和上市策略

區域趨勢正深刻影響著免疫查核點抑制劑的研發、核准和商業化，塑造研發時程、准入途徑和策略重點。在美洲，健全的臨床試驗體系、完善的法規結構和多元化的支付機制促進了新適應症的快速推廣，同時也創造了一個競爭激烈的環境，在這個環境中，真實世界數據和衛生經濟學討論對於醫保報銷和藥品目錄收錄至關重要。此外，美洲的製造和生物技術環境支持先進生物製藥的生產和契約製造，從而能夠在臨床證據支持廣泛應用時實現更快速的規模化生產。

查核點抑制劑領域的競爭優勢依賴臨床差異化、策略聯盟、生產韌性和核准後證據策略。

免疫查核點抑制劑領域的公司競爭主要由臨床差異化、策略夥伴關係和營運能力三者共同驅動。那些將強大的臨床開發能力與嚴謹的核准後證據生成相結合的公司，更有利於拓展適應症範圍並與支付方協商有利的條款。策略夥伴關係，包括共同開發契約、許可協議和生產合作，在獲取新的聯合用藥合作夥伴、拓展地域覆蓋範圍以及降低開發和資本風險方面發揮核心作用。此外，積極投資於真實世界證據計畫、病患支持服務和醫生教育舉措的公司，更有可能獲得更高的市場認可度和更強大的治療定位。

為生物製藥公司和相關人員提供實用建議，以最佳化免疫腫瘤領域的生物標記策略、生產彈性、支付方參與和聯合治療開發。

業界領導者應採取務實且多管齊下的策略，在應對科學複雜性、價格壓力和營運限制的同時，最大限度地提高患者獲益和商業性回報。首先，優先進行生物標記和轉化醫學項目，明確有效人群，並支持適應症擴展，從而簡化臨床試驗流程，增強支付方的價值提案。其次，實現生產和籌資策略多元化，包括本地化生產、檢驗的替代供應商，以及增加關鍵零件的庫存緩衝，以降低關稅和政策帶來的干擾。第三，制定精心設計的生物製藥聯合治療開發藍圖，並進行伴隨診斷，透過在研發早期協調安全管理通訊協定和監管互動，簡化核准流程。

本執行摘要採用嚴謹的調查方法編寫而成，該方法結合了專家訪談、臨床文獻綜合分析、監管分析和基於情境的供應鏈評估。

本執行摘要的調查方法整合了定性和定量數據，以確保研究結果具有實證性、臨床基礎和實際應用價值。主要研究包括對腫瘤臨床醫生、支付方、監管專家、供應鏈高管和商業領袖進行結構化訪談，以收集關於臨床實踐、准入障礙和營運準備的多元觀點。次要研究涵蓋了同行評審的臨床文獻、監管決策和指導文件、臨床試驗註冊庫、產品標籤和公開文件，以檢驗藥物作用機制、安全性以及特定適應症的研發進展。

本文綜合分析了未來展望，重點闡述了決定免疫查核點療法長期成功的科學機會、營運挑戰和策略重點。

免疫查核點抑制劑已徹底改變了癌症治療格局，為特定患者群體帶來持久療效，並開啟了聯合治療和生物標記主導策略的新時代。然而，該領域仍面臨諸多挑戰，包括不同適應症和組織學類型療效的異質性、聯合治療日益複雜且成本不斷攀升，以及支付方對療效明確且持續的證明的期望不斷提高。在營運層面，確保患者及時獲得治療需要周詳的投資計畫和策略遠見，以應對生產規模擴大、供應鏈韌性以及區域監管差異等問題。

目錄

第1章：序言

第2章調查方法

  • 研究設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查前提
  • 調查限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會地圖
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

8. 免疫查核點抑制劑癌症市場依作用機轉分類

  • CTLA-4抑制劑
  • PD-1抑制劑
    • 塞米普利單抗
    • 多斯達利單抗
    • Nivolumab
    • Pembrolizumab
  • PD-L1抑制劑

9. 免疫查核點抑制劑癌症市場（依治療方法）

  • 聯合治療
    • 聯合治療化療
    • 聯合治療免疫療法
    • 聯合標靶治療聯合治療
  • 單藥治療

第10章：免疫查核點抑制劑癌症市場（依治療領域分類）

  • 一線治療
  • 二級治療
  • 三線治療及後續治療

第11章 免疫查核點抑制劑癌症市場（以最終用戶分類）

  • 醫院
  • 專科腫瘤診所

第12章：免疫查核點抑制劑癌症市場（依適應症分類）

  • 膀胱癌
  • 頭頸癌
  • 黑色素瘤
  • 非小細胞肺癌
    • 非鱗狀細胞癌
    • 鱗狀細胞癌
  • 腎臟細胞癌
    • 透明細胞腎細胞癌
    • 非透明細胞腎細胞癌

第13章 免疫查核點抑制劑癌症市場（按地區分類）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章 免疫查核點抑制劑癌症市場（依類別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 各國免疫查核點抑制劑癌症市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章：美國免疫查核點抑制劑癌症市場

第17章：中國免疫查核點抑制劑癌症市場

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Amgen Inc.
  • Arcus Biosciences, Inc.
  • AstraZeneca PLC
  • BeiGene, Ltd.
  • Bristol-Myers Squibb Company
  • Celldex Therapeutics, Inc.
  • Checkpoint Therapeutics, Inc.
  • Eli Lilly and Company
  • Exelixis, Inc.
  • GlaxoSmithKline plc
  • Immutep Ltd.
  • Incyte Corporation
  • Innovent Biologics Co., Ltd.
  • IO Biotech A/S
  • MacroGenics, Inc.
  • Merck KGaA
  • NewLink Genetics Corporation
  • Pfizer Inc.
  • Regeneron Pharmaceuticals, Inc.
  • Roche Holding AG
  • Sanofi SA
  • Seattle Genetics, Inc.
  • Shanghai Junshi Biosciences Co., Ltd.
Product Code: MRR-4F7A6D4FD895

The Immune Checkpoint Inhibitors for Cancer Market was valued at USD 47.25 billion in 2025 and is projected to grow to USD 52.10 billion in 2026, with a CAGR of 10.01%, reaching USD 92.15 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 47.25 billion
Estimated Year [2026] USD 52.10 billion
Forecast Year [2032] USD 92.15 billion
CAGR (%) 10.01%

A concise framing of how immune checkpoint inhibitors reshaped oncology practice across indications, mechanisms, combinations, and care delivery dynamics

The past decade has seen immune checkpoint inhibitors evolve from scientific breakthrough to standard-of-care pillars across multiple oncology indications, challenging conventional paradigms of cancer treatment and care delivery. These agents, which modulate immune checkpoints to restore antitumor immunity, now influence clinical practice across a spectrum of solid tumors, shaping therapeutic decision-making for bladder cancer, head and neck cancer, melanoma, non small cell lung cancer, and renal cell carcinoma. Within non small cell lung cancer, distinctions between non squamous and squamous histologies have driven differential clinical strategies, and within renal cell carcinoma the split between clear cell and non clear cell subtypes has necessitated tailored approaches to patient selection and combination design.

Clinically, the landscape is defined by an expansion in lines of therapy and combinations, including integration with cytotoxic chemotherapy, targeted agents, and other immunomodulatory modalities. Mechanistically, CTLA-4, PD-1, and PD-L1 inhibitors underpin current treatment algorithms, with several PD-1 agents receiving particular attention for their differentiated clinical profiles. From an implementation perspective, hospitals and specialty oncology clinics have adapted infrastructure and care pathways to manage immune-related adverse events, deliver infusion-based therapies, and support complex sequencing decisions. As the field matures, stakeholders across industry, clinical practice, and policy are focused on optimizing biomarker-driven selection, refining combination and sequencing strategies, and ensuring equitable patient access while managing payer expectations and regulatory requirements.

How evolving biomarker precision, combination regimens, regulatory adaptations, and supply chain strategies are redefining competitive advantage in immune checkpoint therapy

The immune checkpoint inhibitors landscape is undergoing transformative shifts driven by converging scientific, clinical, and commercial forces that are redefining standards of care and investment priorities. Advances in biomarker science have improved the precision of patient selection, enabling more nuanced use of PD-1 and PD-L1 antagonists and informing the design of CTLA-4-targeted regimens. Concurrently, combination strategies that pair checkpoint inhibitors with chemotherapy, targeted therapies, or additional immunotherapies are shifting the therapeutic calculus by expanding potential responders and altering toxicity profiles. These combinations, when strategically matched to tumor biology, have produced meaningful efficacy gains in multiple settings, demanding new safety management protocols and multidisciplinary care models.

On the commercial front, differentiation is increasingly achieved through regimen tolerability, real-world evidence generation, and lifecycle management rather than first-to-market exclusivity alone. Regulatory pathways have also adapted, with accelerated approvals frequently contingent on confirmatory data and indication-specific real-world follow-up. Moreover, manufacturing scale-up and supply chain complexity are prompting biopharma organizations to invest in regional production capabilities, cold-chain resilience, and alternative sourcing strategies. As a result, strategic partnerships, licensing arrangements, and targeted acquisitions have become key levers for companies aiming to secure clinical-stage assets, expand geographic reach, or strengthen manufacturing footprints. Taken together, these shifts are creating an environment where agility in development, payer engagement, and operational excellence are prerequisites for sustained success in the checkpoint inhibitor era.

Assessing how changes to United States tariff policy in 2025 could reshape supply chains, manufacturing choices, clinical operations, and commercial contracting dynamics

Anticipated trade policy changes and tariff adjustments within the United States in 2025 introduce a material variable for stakeholders dependent on cross-border supply chains for biologics, raw materials, and specialized components used in immune checkpoint inhibitor manufacture. Although many core active biologic processes remain regionally concentrated, incremental cost pressures can emerge from increased duties on critical inputs, packaging, and laboratory equipment. Such pressures can lead to higher operational expenditures for contract manufacturers, sponsors, and clinical trial suppliers, which in turn influence decisions on production location, inventory strategies, and supplier diversification.

Beyond direct cost implications, tariffs can affect commercial dynamics by accelerating regionalization of manufacturing and prompting strategic reconfiguration of logistics to minimize exposure to tariff-exposed nodes. For clinical development, increased import costs for trial supplies can tighten budgetary envelopes and incentivize localized sourcing or the establishment of in-region warehousing to maintain site activation timelines. From a payer and procurement perspective, higher acquisition costs may intensify scrutiny of therapeutic value, outcomes-based contracting, and negotiation tactics. Consequently, biopharma organizations are likely to respond with a mix of hedging strategies: accelerating onshoring or nearshoring of critical steps, renegotiating supplier contracts, optimizing batch yields, and deepening collaboration with local contract manufacturing organizations to preserve supply continuity and cost competitiveness. These adaptive measures will determine which companies can sustain access commitments and maintain clinical development momentum in a tariff-influenced operating environment.

Deep segmentation insights linking indication subtypes, mechanism nuances, modality choices, therapy lines, and care settings to clinical and commercial strategies for checkpoint inhibitors

A segmentation-aware perspective is essential to understand clinical utility, commercial pathways, and operational priorities for checkpoint inhibitors across distinct patient populations and care settings. Examining indications reveals differentiated therapeutic imperatives: bladder cancer, head and neck cancer, melanoma, non small cell lung cancer, and renal cell carcinoma each present unique tumor biology and response patterns that affect trial design and regulatory strategies. Within non small cell lung cancer, the clinical approach diverges between non squamous and squamous histologies, influencing choice of combination partners and biomarker emphasis, while renal cell carcinoma's split into clear cell and non clear cell subtypes necessitates subtype-specific endpoints and tailored combination regimens.

Mechanism of action segmentation underscores how CTLA-4, PD-1, and PD-L1 inhibitors occupy distinct clinical niches and developmental pathways. The PD-1 inhibitor category, with agents such as cemiplimab, dostarlimab, nivolumab, and pembrolizumab, illustrates intra-class differentiation based on clinical data, safety profile, and approved indications, shaping competitive positioning and label expansion strategies. Treatment modality segmentation highlights the strategic importance of combinations versus monotherapy: combination therapy pathways, whether paired with chemotherapy, other immunotherapies, or targeted agents, increase complexity but also potential clinical benefit, demanding robust safety management and regulatory evidence packages. Therapy line considerations-first line, second line, and third line and beyond-determine trial populations, endpoint selection, and market access tactics, as earlier-line successes often drive rapid adoption and subsequent expectations around durability of benefit. Finally, end-user segmentation between hospitals and specialty oncology clinics affects distribution models, infusion capacity planning, and payer contracting approaches, with each setting presenting distinct operational and reimbursement challenges that must be anticipated during product launch and lifecycle management.

How regional differences in regulation, payer systems, clinical trial ecosystems, and manufacturing capacity shape access and launch strategies across global markets

Regional dynamics exert a profound influence on the development, approval, and commercialization of immune checkpoint inhibitors, shaping timelines, access pathways, and strategic priorities. In the Americas, robust clinical trial ecosystems, established regulatory frameworks, and diversified payer mechanisms facilitate relatively rapid adoption for new indications, but also create a competitive environment where real-world data and health economic arguments are critical to reimbursement and formulary placement. The Americas' manufacturing and biotech ecosystem also supports advanced biologics production and contract manufacturing capacity, enabling faster scale-up when clinical evidence supports broader use.

In Europe, the Middle East & Africa, health technology assessment processes and national reimbursement decisions exert significant influence on uptake, with country-level variations in access creating patchwork adoption patterns. Stakeholders in this region frequently invest in region-specific health economic modeling and local evidence generation to support payer negotiations. Regulatory harmonization initiatives and centralized pathways can accelerate filing strategies, yet heterogeneity in procurement and tendering practices demands bespoke market access plans. In the Asia-Pacific region, growth dynamics are shaped by rapidly expanding clinical trial participation, diverse regulatory maturity across countries, and increasing local biomanufacturing investments. Policymakers and payers in several Asia-Pacific markets are progressively adopting value-based purchasing and outcome-based payment models, prompting companies to generate region-specific effectiveness and budget impact evidence. Across all regions, logistics, local regulatory nuances, and the availability of specialized oncology care settings remain critical factors influencing launch sequencing and commercial resource allocation.

Competitive advantage in checkpoint inhibitors hinges on clinical differentiation, strategic partnerships, manufacturing resilience, and post-approval evidence strategies

Competitive dynamics among companies operating in the immune checkpoint inhibitor space are driven by a mix of clinical differentiation, strategic partnerships, and operational capabilities. Firms that pair robust clinical development with disciplined post-approval evidence generation are better positioned to defend label expansions and negotiate favorable payer terms. Strategic partnerships, including co-development agreements, licensing arrangements, and manufacturing alliances, are central to accessing novel combination partners and expanding geographic reach while mitigating development and capital risk. Additionally, companies that invest proactively in real-world evidence programs, patient support services, and physician education initiatives tend to accelerate uptake and strengthen therapeutic positioning.

Operational excellence remains a decisive differentiator. Organizations with integrated manufacturing strategies, validated supply chain redundancies, and scalable pharmacovigilance systems can respond more effectively to demand variability and emergent safety signals. Portfolio management decisions-prioritizing indication-specific investments, sequencing label efforts, and balancing early-stage innovation with late-stage lifecycle management-will determine long-term value creation. Finally, emerging entrants and specialty biotech firms that bring novel modalities, unique biomarkers, or complementary immunotherapies to the table create new coalition opportunities for established players, enabling creative co-development and commercialization models that can accelerate patient access while distributing development risk.

Actionable recommendations for biopharma and stakeholders to optimize biomarker strategies, manufacturing resilience, payer engagement, and combination development in immuno-oncology

Industry leaders should adopt a pragmatic, multi-dimensional playbook to navigate scientific complexity, pricing pressures, and operational constraints while maximizing patient benefit and commercial return. First, prioritize biomarker and translational programs that clarify responder populations and support label expansion efforts, thereby improving the efficiency of trials and strengthening payer value propositions. Second, diversify manufacturing and sourcing strategies to include regional production, validated alternate suppliers, and increased inventory buffers for critical components to mitigate tariff- or policy-induced disruptions. Third, implement combination development roadmaps that sequence biologic partnerships and companion diagnostics thoughtfully, aligning safety management protocols and regulatory dialogue early in development to streamline approval pathways.

Moreover, embed real-world evidence generation into both pre-approval and post-approval plans to substantiate comparative effectiveness, long-term outcomes, and economic value in diverse healthcare systems. Engage proactively with payers and health technology assessment bodies to co-design outcomes-based agreements or performance-linked reimbursement instruments that reflect real-world performance while sharing risk. Invest in patient support and provider training programs to manage immune-related adverse events, improve adherence to complex regimens, and strengthen continuity of care across hospitals and specialty oncology clinics. Finally, explore flexible commercial models and localized pricing strategies that account for regional affordability realities, enabling broader access without compromising sustainability. These combined actions will enhance resilience and competitiveness in a landscape defined by rapid innovation and evolving stakeholder expectations.

A rigorous research methodology combining primary expert interviews, clinical literature synthesis, regulatory analysis, and scenario-based supply chain evaluation

The methodological approach underpinning this executive summary integrates qualitative and quantitative inputs to ensure findings are evidence-based, clinically grounded, and operationally relevant. Primary research included structured interviews with oncology clinicians, payers, regulatory specialists, supply chain executives, and commercial leaders to capture diverse perspectives on clinical practice, access barriers, and operational readiness. Secondary research encompassed peer-reviewed clinical literature, regulatory decisions and guidance documents, clinical trial registries, product labels, and public filings to validate mechanistic insights, safety profiles, and indication-specific developments.

Analytical techniques involved cross-validation of clinical endpoints and safety signals across trials, synthesis of regional regulatory and reimbursement landscapes to inform access strategies, and scenario analysis to examine the implications of supply chain and tariff disruptions. Expert advisory panels provided iterative review of drafts to ensure clinical accuracy and practical applicability. The methodology also prioritized triangulation of sources, applying conservative interpretation when evidence diverged, and highlighting areas where uncertainty remains high and further data generation is warranted. This layered approach ensures that the conclusions and recommendations are robust, actionable, and tailored to the complex realities of immune checkpoint inhibitor development and commercialization.

A forward-looking synthesis emphasizing the scientific promise, operational challenges, and strategic priorities that will determine long-term success in immune checkpoint therapy

Immune checkpoint inhibitors have irrevocably altered the oncology landscape, delivering durable responses for subsets of patients and catalyzing a new era of combination and biomarker-driven strategies. Yet the field faces persistent challenges: heterogeneity of response across indications and histologies, the rising complexity and cost of combination regimens, and evolving payer expectations that demand clear, sustained evidence of value. Operationally, manufacturing scale-up, supply chain resilience, and regional regulatory variability require deliberate investment and strategic foresight to ensure timely patient access.

Looking ahead, the most promising pathways will be those that harmonize scientific rigor with pragmatic commercialization planning. Integrating translational science into development strategies, forging targeted partnerships for combination approaches, and investing in data generation that demonstrates real-world effectiveness will be essential. Additionally, organizations that adopt resilient operational models-balancing regional manufacturing, proactive payer engagement, and patient-centric access programs-will be better positioned to translate innovative clinical gains into durable clinical and commercial impact. In sum, the checkpoint inhibitor era demands that leaders combine scientific ambition with operational discipline to deliver meaningful advances for patients while navigating a complex and rapidly evolving ecosystem.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Immune Checkpoint Inhibitors for Cancer Market, by Mechanism Of Action

  • 8.1. Ctla4 Inhibitor
  • 8.2. Pd1 Inhibitor
    • 8.2.1. Cemiplimab
    • 8.2.2. Dostarlimab
    • 8.2.3. Nivolumab
    • 8.2.4. Pembrolizumab
  • 8.3. Pdl1 Inhibitor

9. Immune Checkpoint Inhibitors for Cancer Market, by Treatment Modality

  • 9.1. Combination Therapy
    • 9.1.1. Chemotherapy Combination
    • 9.1.2. Immunotherapy Combination
    • 9.1.3. Targeted Therapy Combination
  • 9.2. Monotherapy

10. Immune Checkpoint Inhibitors for Cancer Market, by Therapy Line

  • 10.1. First Line
  • 10.2. Second Line
  • 10.3. Third Line And Beyond

11. Immune Checkpoint Inhibitors for Cancer Market, by End User

  • 11.1. Hospitals
  • 11.2. Specialty Oncology Clinics

12. Immune Checkpoint Inhibitors for Cancer Market, by Indication

  • 12.1. Bladder Cancer
  • 12.2. Head And Neck Cancer
  • 12.3. Melanoma
  • 12.4. Non Small Cell Lung Cancer
    • 12.4.1. Non Squamous
    • 12.4.2. Squamous
  • 12.5. Renal Cell Carcinoma
    • 12.5.1. Clear Cell Rcc
    • 12.5.2. Non Clear Cell Rcc

13. Immune Checkpoint Inhibitors for Cancer Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Immune Checkpoint Inhibitors for Cancer Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Immune Checkpoint Inhibitors for Cancer Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Immune Checkpoint Inhibitors for Cancer Market

17. China Immune Checkpoint Inhibitors for Cancer Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Amgen Inc.
  • 18.6. Arcus Biosciences, Inc.
  • 18.7. AstraZeneca PLC
  • 18.8. BeiGene, Ltd.
  • 18.9. Bristol-Myers Squibb Company
  • 18.10. Celldex Therapeutics, Inc.
  • 18.11. Checkpoint Therapeutics, Inc.
  • 18.12. Eli Lilly and Company
  • 18.13. Exelixis, Inc.
  • 18.14. GlaxoSmithKline plc
  • 18.15. Immutep Ltd.
  • 18.16. Incyte Corporation
  • 18.17. Innovent Biologics Co., Ltd.
  • 18.18. IO Biotech A/S
  • 18.19. MacroGenics, Inc.
  • 18.20. Merck KGaA
  • 18.21. NewLink Genetics Corporation
  • 18.22. Pfizer Inc.
  • 18.23. Regeneron Pharmaceuticals, Inc.
  • 18.24. Roche Holding AG
  • 18.25. Sanofi S.A.
  • 18.26. Seattle Genetics, Inc.
  • 18.27. Shanghai Junshi Biosciences Co., Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY MECHANISM OF ACTION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY TREATMENT MODALITY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY THERAPY LINE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY CTLA4 INHIBITOR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY CTLA4 INHIBITOR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY CTLA4 INHIBITOR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY PD1 INHIBITOR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY PD1 INHIBITOR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY PD1 INHIBITOR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY PD1 INHIBITOR, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY CEMIPLIMAB, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY CEMIPLIMAB, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY CEMIPLIMAB, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY DOSTARLIMAB, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY DOSTARLIMAB, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY DOSTARLIMAB, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY NIVOLUMAB, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY NIVOLUMAB, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY NIVOLUMAB, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY PEMBROLIZUMAB, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY PEMBROLIZUMAB, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY PEMBROLIZUMAB, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY PDL1 INHIBITOR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY PDL1 INHIBITOR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY PDL1 INHIBITOR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY COMBINATION THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY COMBINATION THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY COMBINATION THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY CHEMOTHERAPY COMBINATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY CHEMOTHERAPY COMBINATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY CHEMOTHERAPY COMBINATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY IMMUNOTHERAPY COMBINATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY IMMUNOTHERAPY COMBINATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY IMMUNOTHERAPY COMBINATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY TARGETED THERAPY COMBINATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY TARGETED THERAPY COMBINATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY TARGETED THERAPY COMBINATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY MONOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY MONOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY MONOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY FIRST LINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY FIRST LINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY FIRST LINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY SECOND LINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY SECOND LINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY SECOND LINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY THIRD LINE AND BEYOND, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY THIRD LINE AND BEYOND, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY THIRD LINE AND BEYOND, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY SPECIALTY ONCOLOGY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY SPECIALTY ONCOLOGY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY SPECIALTY ONCOLOGY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY BLADDER CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY BLADDER CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY BLADDER CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY HEAD AND NECK CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY HEAD AND NECK CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY HEAD AND NECK CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY MELANOMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY MELANOMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY MELANOMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY NON SMALL CELL LUNG CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY NON SMALL CELL LUNG CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY NON SMALL CELL LUNG CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY NON SQUAMOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY NON SQUAMOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY NON SQUAMOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY SQUAMOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY SQUAMOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY SQUAMOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY RENAL CELL CARCINOMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY RENAL CELL CARCINOMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY RENAL CELL CARCINOMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY RENAL CELL CARCINOMA, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY CLEAR CELL RCC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY CLEAR CELL RCC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY CLEAR CELL RCC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY NON CLEAR CELL RCC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY NON CLEAR CELL RCC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY NON CLEAR CELL RCC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 90. AMERICAS IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 91. AMERICAS IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 92. AMERICAS IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY PD1 INHIBITOR, 2018-2032 (USD MILLION)
  • TABLE 93. AMERICAS IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 94. AMERICAS IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 95. AMERICAS IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 96. AMERICAS IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 97. AMERICAS IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 98. AMERICAS IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2018-2032 (USD MILLION)
  • TABLE 99. AMERICAS IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY RENAL CELL CARCINOMA, 2018-2032 (USD MILLION)
  • TABLE 100. NORTH AMERICA IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. NORTH AMERICA IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 102. NORTH AMERICA IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY PD1 INHIBITOR, 2018-2032 (USD MILLION)
  • TABLE 103. NORTH AMERICA IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 104. NORTH AMERICA IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 105. NORTH AMERICA IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 106. NORTH AMERICA IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 107. NORTH AMERICA IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 108. NORTH AMERICA IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2018-2032 (USD MILLION)
  • TABLE 109. NORTH AMERICA IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY RENAL CELL CARCINOMA, 2018-2032 (USD MILLION)
  • TABLE 110. LATIN AMERICA IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 111. LATIN AMERICA IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 112. LATIN AMERICA IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY PD1 INHIBITOR, 2018-2032 (USD MILLION)
  • TABLE 113. LATIN AMERICA IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 114. LATIN AMERICA IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 115. LATIN AMERICA IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 116. LATIN AMERICA IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 117. LATIN AMERICA IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 118. LATIN AMERICA IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2018-2032 (USD MILLION)
  • TABLE 119. LATIN AMERICA IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY RENAL CELL CARCINOMA, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPE, MIDDLE EAST & AFRICA IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPE, MIDDLE EAST & AFRICA IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPE, MIDDLE EAST & AFRICA IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY PD1 INHIBITOR, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPE, MIDDLE EAST & AFRICA IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPE, MIDDLE EAST & AFRICA IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPE, MIDDLE EAST & AFRICA IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPE, MIDDLE EAST & AFRICA IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPE, MIDDLE EAST & AFRICA IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 128. EUROPE, MIDDLE EAST & AFRICA IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2018-2032 (USD MILLION)
  • TABLE 129. EUROPE, MIDDLE EAST & AFRICA IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY RENAL CELL CARCINOMA, 2018-2032 (USD MILLION)
  • TABLE 130. EUROPE IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 131. EUROPE IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 132. EUROPE IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY PD1 INHIBITOR, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPE IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 134. EUROPE IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPE IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPE IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPE IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPE IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPE IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY RENAL CELL CARCINOMA, 2018-2032 (USD MILLION)
  • TABLE 140. MIDDLE EAST IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 141. MIDDLE EAST IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 142. MIDDLE EAST IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY PD1 INHIBITOR, 2018-2032 (USD MILLION)
  • TABLE 143. MIDDLE EAST IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 144. MIDDLE EAST IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 145. MIDDLE EAST IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 146. MIDDLE EAST IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 147. MIDDLE EAST IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 148. MIDDLE EAST IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2018-2032 (USD MILLION)
  • TABLE 149. MIDDLE EAST IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY RENAL CELL CARCINOMA, 2018-2032 (USD MILLION)
  • TABLE 150. AFRICA IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 151. AFRICA IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 152. AFRICA IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY PD1 INHIBITOR, 2018-2032 (USD MILLION)
  • TABLE 153. AFRICA IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 154. AFRICA IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 155. AFRICA IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 156. AFRICA IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 157. AFRICA IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 158. AFRICA IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2018-2032 (USD MILLION)
  • TABLE 159. AFRICA IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY RENAL CELL CARCINOMA, 2018-2032 (USD MILLION)
  • TABLE 160. ASIA-PACIFIC IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 161. ASIA-PACIFIC IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 162. ASIA-PACIFIC IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY PD1 INHIBITOR, 2018-2032 (USD MILLION)
  • TABLE 163. ASIA-PACIFIC IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 164. ASIA-PACIFIC IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 165. ASIA-PACIFIC IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 166. ASIA-PACIFIC IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 167. ASIA-PACIFIC IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 168. ASIA-PACIFIC IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2018-2032 (USD MILLION)
  • TABLE 169. ASIA-PACIFIC IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY RENAL CELL CARCINOMA, 2018-2032 (USD MILLION)
  • TABLE 170. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 171. ASEAN IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 172. ASEAN IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 173. ASEAN IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY PD1 INHIBITOR, 2018-2032 (USD MILLION)
  • TABLE 174. ASEAN IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 175. ASEAN IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 176. ASEAN IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 177. ASEAN IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 178. ASEAN IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 179. ASEAN IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2018-2032 (USD MILLION)
  • TABLE 180. ASEAN IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY RENAL CELL CARCINOMA, 2018-2032 (USD MILLION)
  • TABLE 181. GCC IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 182. GCC IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 183. GCC IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY PD1 INHIBITOR, 2018-2032 (USD MILLION)
  • TABLE 184. GCC IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 185. GCC IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 186. GCC IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 187. GCC IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 188. GCC IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 189. GCC IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2018-2032 (USD MILLION)
  • TABLE 190. GCC IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY RENAL CELL CARCINOMA, 2018-2032 (USD MILLION)
  • TABLE 191. EUROPEAN UNION IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 192. EUROPEAN UNION IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 193. EUROPEAN UNION IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY PD1 INHIBITOR, 2018-2032 (USD MILLION)
  • TABLE 194. EUROPEAN UNION IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 195. EUROPEAN UNION IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 196. EUROPEAN UNION IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 197. EUROPEAN UNION IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 198. EUROPEAN UNION IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 199. EUROPEAN UNION IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2018-2032 (USD MILLION)
  • TABLE 200. EUROPEAN UNION IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY RENAL CELL CARCINOMA, 2018-2032 (USD MILLION)
  • TABLE 201. BRICS IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 202. BRICS IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 203. BRICS IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY PD1 INHIBITOR, 2018-2032 (USD MILLION)
  • TABLE 204. BRICS IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 205. BRICS IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 206. BRICS IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 207. BRICS IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 208. BRICS IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 209. BRICS IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2018-2032 (USD MILLION)
  • TABLE 210. BRICS IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY RENAL CELL CARCINOMA, 2018-2032 (USD MILLION)
  • TABLE 211. G7 IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 212. G7 IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 213. G7 IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY PD1 INHIBITOR, 2018-2032 (USD MILLION)
  • TABLE 214. G7 IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 215. G7 IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 216. G7 IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 217. G7 IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 218. G7 IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 219. G7 IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2018-2032 (USD MILLION)
  • TABLE 220. G7 IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY RENAL CELL CARCINOMA, 2018-2032 (USD MILLION)
  • TABLE 221. NATO IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 222. NATO IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 223. NATO IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY PD1 INHIBITOR, 2018-2032 (USD MILLION)
  • TABLE 224. NATO IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 225. NATO IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 226. NATO IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 227. NATO IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 228. NATO IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 229. NATO IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2018-2032 (USD MILLION)
  • TABLE 230. NATO IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY RENAL CELL CARCINOMA, 2018-2032 (USD MILLION)
  • TABLE 231. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 232. UNITED STATES IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 233. UNITED STATES IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 234. UNITED STATES IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY PD1 INHIBITOR, 2018-2032 (USD MILLION)
  • TABLE 235. UNITED STATES IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 236. UNITED STATES IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 237. UNITED STATES IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 238. UNITED STATES IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 239. UNITED STATES IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 240. UNITED STATES IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2018-2032 (USD MILLION)
  • TABLE 241. UNITED STATES IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY RENAL CELL CARCINOMA, 2018-2032 (USD MILLION)
  • TABLE 242. CHINA IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 243. CHINA IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 244. CHINA IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY PD1 INHIBITOR, 2018-2032 (USD MILLION)
  • TABLE 245. CHINA IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 246. CHINA IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 247. CHINA IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 248. CHINA IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 249. CHINA IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 250. CHINA IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2018-2032 (USD MILLION)
  • TABLE 251. CHINA IMMUNE CHECKPOINT INHIBITORS FOR CANCER MARKET SIZE, BY RENAL CELL CARCINOMA, 2018-2032 (USD MILLION)